Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5357068 | 0.94 | KDR (0.88) | KDRPKMCHEK1MEN1KMT2A | |
| SCHEMBL5355012 | 0.88 | KDR (1.00) | KDRPKMCHEK1MEN1KMT2A | |
| SCHEMBL5357658 | 0.88 | KDR (0.78) | KDRPKMCHEK1MEN1KMT2A | |
| SCHEMBL5357342 | 0.85 | KDR (0.74) | KDRPKMCHEK1 | |
| SCHEMBL5355363 | 0.84 | KDR (0.85) | KDRCHEK1MEN1KMT2APOLB | |
| SCHEMBL5367711 | 0.83 | KDR (0.70) | KDRPKMCHEK1MEN1KMT2A | |
| SCHEMBL5355698 | 0.83 | KDR (1.00) | KDRCHEK1MEN1KMT2AHSD17B10 | |
| SCHEMBL14590416 | 0.82 | KDR (0.88) | KDRPKMCHEK1MEN1KMT2A | |
| SCHEMBL5370747 | 0.81 | KDR (0.67) | KDRPKMMEN1KMT2APOLB | |
| SCHEMBL5352066 | 0.79 | KDR (0.64) | KDRPKMCHEK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169788-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-01-30 | — | — | US | claimed |
| US-20040220216-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | claimed |
| WO-2003037252-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-08 | — | — | WO | claimed |
| US-7169788-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169788-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169788-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040220216-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | disclosed |
| WO-2003037252-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220216-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885PKM 1083/4885CHEK1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.